Inhibition by hydrazine sulfate and various hydrazides, of in vivo growth of Walker 256 intramuscular carcinoma, B-16 melanoma, Murphy-Sturm lymphosarcoma and L-1210 solid leukemia.
D000818:Animals; D002279:Carcinoma 256, Walker / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D005943:Gluconeogenesis / Q000187:drug effects; D006834:Hydrazines / Q000627:therapeutic use*; D007939:Leukemia L1210 / Q000188:drug therapy*; D007945:Leukemia, Lymphoid / Q000188:drug therapy; D008223:Lymphoma / Q000188:drug therapy*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D051379:Mice; D008937:Mitomycins / Q000627:therapeutic use; D009368:Neoplasm Transplantation; D010729:Phosphoenolpyruvate Carboxykinase (GTP) / Q000037:antagonists & inhibitors; D011725:Pyridines / Q000627:therapeutic use; D051381:Rats; D012513:Sarcoma, Experimental / Q000188:drug therapy; D014184:Transplantation, Homologous
D006834:Hydrazines; D008937:Mitomycins; D011725:Pyridines; D003520:Cyclophosphamide; D010729:Phosphoenolpyruvate Carboxykinase (GTP)